Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
December 19, 2022 07:00 ET
|
Revolution Medicines, Inc.
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric...
Persbericht Biocartis Group NV: Voltooiing van verplichte conversie
December 16, 2022 11:40 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE16 december 2022, 17:40 CET Voltooiing van Verplichte Conversie Bepalingen met een hoofdletter in deze kennisgeving die niet werden gedefinieerd zullen de...
Press release Biocartis Group NV: Completion of Mandatory Conversion
December 16, 2022 11:40 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION16 December 2022, 17:40 CET Completion of Mandatory Conversion Capitalized terms not otherwise defined in this notice shall have the meaning given to them in the...
Arvinas Announces Changes to its Board of Directors
December 16, 2022 09:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
December 15, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
December 15, 2022 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023
December 13, 2022 08:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
December 13, 2022 04:00 ET
|
AKAMPION
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
December 12, 2022 10:00 ET
|
Affimed N.V.
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid...
Companion Diagnostics Market is expected to generate a revenue of USD 12,150.01 Million by 2030, Globally, at 13.11% CAGR: Verified Market Research®
December 12, 2022 09:30 ET
|
Verified Market Research
Jersey City, New Jersey, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Verified Market Research® recently published a report, “Companion Diagnostics Market” By Technology Type (Frequency Immunohistochemistry,...